AZTR Profile
Azitra, Inc. is a pre-clinical biopharmaceutical firm dedicated to advancing precision dermatology through the development of innovative therapies utilizing engineered proteins and live biotherapeutic products. The company focuses on creating targeted treatments for a range of skin diseases, leveraging its expertise in genetic modification and biotherapeutic technology. Azitra's research aims to address significant unmet needs in dermatological care by developing solutions that precisely target the underlying mechanisms of various skin disorders.
Among its key product candidates, Azitra is advancing ATR-12, a genetically engineered strain of Staphylococcus epidermidis, designed to treat Netherton syndromeâ€a rare genetic condition characterized by severe skin inflammation and barrier dysfunction. Another prominent candidate is ATR-04, also a genetically modified strain of S. epidermidis, aimed at alleviating the papulopustular rash commonly experienced by cancer patients undergoing treatment with epidermal growth factor receptor inhibitors. Additionally, Azitra is developing ATR-01, an engineered recombinant human filaggrin protein intended to treat ichthyosis vulgaris, a genetic disorder resulting in dry, scaly skin.
Founded in 2014 and headquartered in Branford, Connecticut, Azitra operates at the forefront of dermatological innovation. The company’s approach involves harnessing cutting-edge biotechnological techniques to create advanced therapeutic products that address complex skin conditions. By focusing on precision dermatology, Azitra is positioned to make significant contributions to the field of skin disease treatment and improve the quality of life for patients affected by these challenging conditions.
Azitra’s commitment to advancing the science of dermatology is reflected in its rigorous research and development efforts. As the company progresses through the pre-clinical stages, it remains focused on optimizing its product candidates and pursuing regulatory pathways to bring its innovative therapies to market. With a strategic emphasis on leveraging advanced technology and addressing critical dermatological needs, Azitra is poised to play a pivotal role in the future of skin disease treatment.
|
